Clinical trial · Observational

Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

PILOT-high Throughput-protein Profiling Analysis of Sera Collected From E1694 Patients Undergoing HDI (Arm B)

NCT00897520CI-TRIAL-00027692completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Melanoma (Skin)	Melanoma	ONTOLOGY_EXACT	0.85

Interventions

Interventions (4)

Intervention	Type	Mapped drug	Match
immunoenzyme technique	Other	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
proteomic profiling	Genetic	—	UNRESOLVED
recombinant interferon alfa	Biological	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (2)

measure
Serum sample screening via high throughput protein profiling in patients undergoing therapy
timeFrame
1 month
measure
Comparison of soluble factors
timeFrame
1 month

Eligibility

Eligibility (as posted)

Sex: All
Maximum age: 120 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Diagnosis of high-risk melanoma
* Receiving interferon alfa-2b therapy in arm II of clinical trial E-1694

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

References

Publications (0)

Data not yet available

No reference posted for this study.